
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Real-World Evidence Integration into Cancer HTA: Scotland’s Success Story
How is real-world evidence integration a routine part of Health Technology Assessment (HTA) for cancer medicines in Scotland? Through a successful collaboration between the Cancer Medicines Outcomes Programme–Public Health Scotland (CMOP-PHS) and the Scottish Medicines Consortium (SMC), structure...
Personalised Fertility Endometriosis Care in the UK
The updated NICE fertility guideline introduces a dedicated section for individuals with endometriosis who are struggling to conceive. This change formally recognises personalised fertility endometriosis as a distinct cause of infertility rather than grouping it under unexplained infertility.
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceutical Innovation
A European Federation of Pharmaceutical Industries and Associations (EFPIA) statement has welcomed the European Union’s progress in concluding negotiations for a Free Trade Agreement with India. EU-India Pharmaceutical Trade relations have gained strategic importance amid geopolitical uncertainty...